PharmaCyte Biotech Inc PMCB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.34
- Day Range
- $0.34–0.37
- 52-Week Range
- $0.33–1.51
- Bid/Ask
- $0.33 / $0.42
- Shares Outstanding
- 10.74M
- Market Cap
- $3.67M
- Volume/Avg
- 25,042 / 199,238
Key Statistics
- Price/Earnings (Normalized)
- 1.07
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 10.93%
Company Profile
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://pharmacyte.com
Valuation
|
Metric
|
PMCB
|
|---|---|
Price/Earnings (Normalized) | 1.07 |
Price/Book Value | 0.13 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PMCB
Financial Strength
|
Metric
|
PMCB
|
|---|---|
Quick Ratio | 40.25 |
Current Ratio | 40.30 |
Interest Coverage | — |
Quick Ratio
PMCB
Profitability
|
Metric
|
PMCB
|
|---|---|
Return on Assets (Normalized) | −3.31% |
Return on Equity (Normalized) | −4.48% |
Return on Invested Capital (Normalized) | −6.17% |
Return on Assets
PMCB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#Jg?>zl | LOCK|^yD>Z | $130B | |||
| Moderna Inc
MRNA
| LOCK|dfm%>yq | LOCK|D@ | $97B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|K>nZ#wq | LOCK|R>X^@ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|!Xx<#Z | LOCK|xZ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<GcyG<z | LOCK|&R^ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|szML@GT | LOCK|?f%W | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%?V^@k< | LOCK|!rQs | $28B | |||
| Incyte Corp
INCY
| LOCK|K<!?trn | LOCK|!$ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|^yGDgNk | LOCK|Vq | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|pVS?hR! | LOCK|xK$ | $14B |
United States